# Epoch: An Ontological Framework to Support Clinical Trials Management

Amar Das, MD, PhD
Assistant Professor
Stanford Medical Informatics
Stanford University



#### **Acknowledgments**

**Epoch Group @ Stanford Medical Informatics** 

Ravi Shankar Martin O'Connor

**Susana Martins Samson Tu** 

**Noah Zimmerman** 

#### **Immune Tolerance Network**

Jeff Bluestone Dave Parrish

Peter Sayre Vicki Seyfert

Kathy McCafferty Keith Boyce

**Chuck Borromeo** Manizhe Payton

**Trang Gisler** 

... and many others ...

#### Challenges of clinical trials management


- The design and execution of complex clinical trials involve collaborations among many groups
- The use of disparate software tools for trial design and execution can lead to
  - Lack of formalization in trial specification
  - Ambiguities in trial implementation
  - Increased efforts in trial management
- The use of ontologies can enable a shared semantic understanding of clinical trials among personnel and software

### The Immune Tolerance Network (ITN) accelerates the development of immune tolerance therapies

- Investigator-initiated clinical trials of novel tolerance-promoting therapies in
  - Autoimmune diseases
  - Transplantation
  - Allergy and Asthma
- Provides services to undertake comprehensive mechanistic studies that complement each trial




### Major stages in an ITN clinical trial are study specification, implementation, and assessment



# This presentation discusses the use of ontologies to support clinical trials in ITN



The need for semantic integration





A suite of ontologies



A knowledge-based architecture

#### A variety of questions are posed by different personnel during each stage of a clinical trial








**Specification** 

**Implementation** 


Management

#### **Example questions related to trial specification**



- Is there another protocol similar to this one?
- What clinical activities or mechanistic assays should be planned?
- What specimens need to be collected to perform an assay?
- At which visits should these activities occur?

#### Example questions related to trial implementation




- When is the next visit for this participant?
- What mechanistic assays should performed for this visit?
- Where should this specimen container be shipped?

#### Example questions related to trial management




- How many participants are in the follow-up period?
- What are the results of an assay for a particular participant before transplant?
- What is the enrollment data by sites for these four trials?
- What are the total number of specimens accessioned?


### Personnel collaborate to specify, implement, and manage a clinical trial



### Multiple communication modalities are used in this collaboration




# Trial information encoded by different groups is needed in queries and reports




#### When enterprise-wide knowledge about trials is not formally encoded, problems can arise

- Verifying data integrity in real time is difficult
- Resolving inconsistencies after a trial has started may be required
- Integrating data generated from different software tools is hard
- Performing complex analyses across multiple trials may be very limited



# We have created an ontological framework to enable standardization and integration




#### Our ontology work focuses on developing knowledge-based methods

1. To help acquire and maintain knowledge for trial specification




2. To configure software tools for trial implementation



3. To support ad hoc data analysis for trial management



### Our suite of ontologies is based on past and existing modeling work and on ITN requirements




### Schedule of Events lists the clinical activities and when they should be performed

(Title removed)																
	Day															
	-1	0	2	7	14	21	28	35	42	56	70	84	112	168	252	364
	Visit															
	-1¹	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14
Medication Administration																
	3x/7 days															
daily																
General Assessments																
Informed consent	Х															
Inclusion/exclusion criteria	Х															
Laboratory Assessments																
Sirolimus trough level			Х	Х	Х	Х	Х	Х	Х	Х	Х	Х				
Hematology	Х				Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
Comprehensive chemistry	Х				Х	Х		Х			Х		Х		Х	
Basic chemistry							Х		Х	Х		Х		Х		Х
Amylase <sup>4</sup>	Х				Х		Х		Х	Х		Х				
Thyroid function	х							х				х		Х		х
ITN Core Mechanistic Studies																
Whole blood-EBV viral load <sup>5</sup>	Х				Х	Х	Х	Х	Х	Х	Х	Х		Х		Х
Whole blood_CMV trival load <sup>6</sup>	Х				Х	Х	Х	Х	Х	Х	Х	Х		Х		Х

<sup>&</sup>lt;sup>3</sup> PPD test must be read 48-72 hours after placement.

<sup>&</sup>lt;sup>4</sup> If amylase level is increased, follow-up lipase level will be performed.

### Schedule of Events lists the clinical activities and when they should be performed




<sup>&</sup>lt;sup>3</sup> PPD test must be read 48-72 hours after placement.

<sup>&</sup>lt;sup>4</sup> If amylase level is increased, follow-up lipase level will be performed.


### **Specimen Workflow Table contains information** on the processing of biological specimens

		Blood/											
	Collection	Specimen		Shipping		Final		Collect					
Standard Term	Tubes	Volume	Processing/Shipping	Instruction	Destination	Destination	Assay Instructions						
	MECHANISTIC ASSAYS												
Whole Blood- Quantitative PCR for CMV and EBV	1 x 2 ml K₂EDTA	1	Invert to mix, leave at ambient temperature, and ship	Ship o/n ambient temperature			Results sent directly to the site. Note: If EBV levels rise above 2000 copies/ml and pos for IgG or IgM, samples to be collected weekly until levels have been						
Reactivation	lavendar top	2 ml	immediately	Mon-Wed	Viracor	Viracor	reduced below 2000 copies per ml	-1,3,4,5,6,7					
Serum- Autoantibody Analysis	1 x 6.0 ml red top tube	6.0 ml	Aliquot serum into 13 cryovials and freeze <-70℃.	Dry ice Mon - Wed only.	ITN Repository	Autoantibod y Core	Antigens: GAD65, ICA512/IA-2, insulin, ICA Note: two vials will be sent at screening, one to each autoantibody core for testing	-1,10,12,14					
PBMC-Flow Cytometry Intracellular Staining	6 x 10 ml Kendall glass Na heparin		1 .	temperature,	ITN PBMC Isolation		See the MAR Tetramer: DR4-GAD, DR4-IA-2, DR3-						
PBMC-T Cell Assay	tubes	60 ml	collection	Mon-Fri only.	Core	ITN Core	proinsulin, ELISPOT	0,5,8,10,12					
Whole Blood-Gene Expression Profiling			Invert to mix thoroughly for 10 to 20 seconds and freeze at - 70°C	1 -	ITN Repository	RT PCR Core Microarray Core	Human U133 Chip 2.0 Plus	0,10,12,14					


### Specimen Workflow Table contains information on the processing of biological specimens




#### A suite of Epoch ontologies encapsulate clinical trial knowledge




#### The ontologies are specified in OWL using the Protégé-OWL editor




#### The Protocol Ontology consists of concepts and their attributes in the clinical trial domain




### Documentation on each class and its attributes are maintained in the OWL ontology itself




### We are building custom user interfaces to enter and browse specific clinical trials



### Instantiation of the Epoch ontologies generates clinical trial knowledge bases



#### The Epoch architecture supports knowledgedriven specification of software tools



#### In conclusion, our work on Epoch allows

- A central, modifiable repository of knowledge to encode shared semantics among users and software tools
- A knowledge-based architecture for trial design, implementation and management
- The use of ontologies for inferring relationships among trial data for queries and reports
- The ability to use reference ontologies to annotate the knowledge used in clinical trial management

